Skip to Content
MilliporeSigma

Skip To

SML1102

Darifenacin hydrobromide

≥98% (HPLC), Muscarinic antagonist, powder

Synonym(s):

(3S)-1-[2-(2,3-Dihydro-5-benzofuranyl)ethyl]-α,α-diphenyl-3-pyrrolidineacetamide hydrobromide, UK 88525-04

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View
Pack SizeSKUAvailabilityPrice
10 mg

Available to ship TODAYfromMILWAUKEE

$81.90
50 mg

Available to ship TODAYfromMILWAUKEE

$335.00

About This Item

Empirical Formula (Hill Notation):
C28H30N2O2 · HBr
CAS Number:
Molecular Weight:
507.46
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
Storage condition:
desiccated

$81.90


Available to ship TODAYDetails


Request a Bulk Order
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


Product Name

Darifenacin hydrobromide, ≥98% (HPLC)

Quality Level

assay

≥98% (HPLC)

form

powder

optical activity

[α]/D +41 to +49°, c = 1 in methylene chloride

storage condition

desiccated

color

white to beige

solubility

DMSO: 20 mg/mL, clear

storage temp.

−20°C

SMILES string

O=C(N)C([C@H]1CN(CCC2=CC=C(OCC3)C3=C2)CC1)(C4=CC=CC=C4)C5=CC=CC=C5.Br

InChI

1S/C28H30N2O2.BrH/c29-27(31)28(23-7-3-1-4-8-23,24-9-5-2-6-10-24)25-14-17-30(20-25)16-13-21-11-12-26-22(19-21)15-18-32-26;/h1-12,19,25H,13-18,20H2,(H2,29,31);1H/t25-;/m1./s1

InChI key

UQAVIASOPREUIT-VQIWEWKSSA-N

Gene Information

General description

Darifenacin is a muscarinic receptor antagonist. It is an extended release tablet that has 7.5 mg or 15 mg darifenacin as its hydrobromide salt.

Application

Darifenacin hydrobromide has been used to inject experimental animals.

Biochem/physiol Actions

Darifenacin hydrobromide is an antispasmodic muscarinic antagonist, selective for blocking the M3 muscarinic acetylcholine receptor, which is primarily responsible for bladder muscle contractions. Darifenacin hydrobromide has 9 and 12-fold greater affinity for M3 compared to M1 and M5, respectively, and 59-fold greater affinity for M3 compared to both M2 and M4. Darifenacin is used clinically to treat urinary incontinence and overactive bladder syndrome.
Darifenacin hydrobromide is an antispasmodic muscarinic antagonist, selective for blocking the M3 muscarinic acetylcholine receptor.

Features and Benefits

This compound is a featured product for Neuroscience research. Click here to discover more featured Neuroscience products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

Compare Similar Items

View Full Comparison

Show Differences

1 of 1

This Item
1164200SML2591G019
assay

≥98% (HPLC)

assay

-

assay

≥98% (HPLC)

assay

≥98% (HPLC)

form

powder

form

solid

form

powder

form

solid

Quality Level

100

Quality Level

-

Quality Level

-

Quality Level

100

storage temp.

−20°C

storage temp.

-

storage temp.

2-8°C

storage temp.

2-8°C

storage condition

desiccated

storage condition

-

storage condition

desiccated

storage condition

-

solubility

DMSO: 20 mg/mL, clear

solubility

-

solubility

DMSO: 2 mg/mL, clear

solubility

H2O: >10 mg/mL


Still not finding the right product?

Explore all of our products under Darifenacin hydrobromide


pictograms

Exclamation mark

signalword

Warning

Hazard Classifications

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable



Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library


Articles

DISCOVER Bioactive Small Molecules for Neuroscience


Principles and Practice of Urology, 2 (2013)
Evaluating the effect of three newly approved overactive bladder syndrome treating agents on parotid and submandibular salivary glands: Modulation of CXCL10 expression
Aboulhoda BE and Ali EN
Acta Histochemica, 120(3), 269-281 (2018)
Henry C Liu et al.
The Journal of pharmacology and experimental therapeutics, 359(1), 215-229 (2016-08-05)
Statistical analysis was performed on physicochemical descriptors of ∼250 drugs known to interact with one or more SLC22 "drug" transporters (i.e., SLC22A6 or OAT1, SLC22A8 or OAT3, SLC22A1 or OCT1, and SLC22A2 or OCT2), followed by application of machine-learning methods



Global Trade Item Number

SKUGTIN
SML1102-50MG04061832077024
SML1102-10MG04061837107603

Questions

Reviews

No rating value

Active Filters